Gyre Therapeutics presents Hydronidone preclinical data at AASLD; plans US clinical program in 2024

GYRE THERAPEUTICS, INC.

Poster at AASLD Liver Meeting (Nov 10-14, 2023) shows Hydronidone reduces liver fibrosis in mouse models.
Hydronidone inhibits hepatic stellate cell activation via Smad7-mediated TGF-β degradation.
Company expects to initiate U.S. clinical program for MASH-associated fibrosis in 2024.
Specific Smad7 knockdown in vivo blocked Hydronidone's antifibrotic effect, confirming mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.